Fimea’s final accounts and annual report for 2020 are also published online
Fimea’s final accounts and annual report for 2020 have been published. Fimea achieved its profitability target comfortably in spite of the corona virus epidemic. In order to ensure the safety of medicines and patients, we adopted new, more agile operating practices, and we were able to progress in accordance with our targets in our basic work and our development tasks.
Flexible procedures enabled us to ensure the availability of medicinal products. We set up a new data collection system for monitoring the information on national supplies of medicines and for forecasting their sufficiency. The remote inspection model was developed during 2020 and integrated as part of Fimea's inspection operations. Remote inspections were the theme in the global GMP inspectors’ virtual seminar organised by Fimea.
Marketing authorisation operations were adapted for urgent and rapid processing of marketing authorisation applications. We upgraded the medicines search and started to publish supply shortage notifications as open data. In 2020, a national procurement process for expensive medicines primarily used in hospitals was also initiated in which Fimea supported the negotiations with expert assessments. As part of the road map for pharmaceutical matters, Fimea compiled a report on a national medicines data repository at the request of the Ministry of Social Affairs and Health. In collaboration with our stakeholders, we also prepared a guide for safe pharmacotherapy
This year, an online version of the annual report has been put together which presents our current themes of interest from over the year.
- Director General Eija Pelkonen tel. +358 29 522 3100
- Finance Director Esko Kiiski tel. +358 29 522 3630
- E-mail addresses follow the form email@example.com